Trial Profile
A randomized, double-blind, placebo controlled, multi-centre, exploratory, pilot, phase II trial of 150 mg atacicept given subcutaneously in combination with rituximab in subjects with rheumatoid arthritis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Atacicept (Primary) ; Rituximab
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Acronyms August III
- 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
- 09 Jun 2012 Planned number of patients changed from 54 to 90 as reported by European Clinical Trials Database record.
- 04 Apr 2012 Actual patient number 68 added as reported by ClinicalTrials.gov.